Novo Nordisk (NYSE: NVO) is a leader in the billion-dollar weight loss market, with two drugs that have helped its earnings ...

GLP-1 medications, used for weight loss and diabetes, may also help prevent colon cancer. Research finds these drugs reduce ...

High prices for anti-obesity drugs known as GLP-1 medications, coupled with high employee demand, are giving employers a lot ...

Patients on Eli Lilly's Mounjaro were more likely to lose weight and experienced larger reductions in body weight compared to ...

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in ...

Dr. Lee Kaplan took the stage with an urgent message, telling fellow physicians they have a powerful weapon to fight the ...

Share on Pinterest Diabetes and obesity disproportionately impact Black people, yet they are facing greater challenges gaining access to GLP-1 medications like Ozempic that could help treat these ...

As the popularity of appetite-suppressing drugs like Ozempic and Wegovy continues to skyrocket, one of America's chief snack food overlords is readying himself — and his company's delicious ...

Is the fervor over Ozempic just a passing fad? It doesn't appear to be the case after Novo Nordisk (NYSE: NVO) announced its results for the first nine months of 2023 on Thursday morning.

This section presents medications that are known to potentially lead to 'Throat sore' as a side effect." It's important to note that mild side effects are quite common with medications. Please be ...

The maker of weight-loss jabs Wegovy and Ozempic, Danish pharmaceutical giant Novo Nordisk, has reported a sharp rise in profits on the back of surging demand for the drugs. Net profits were 39 ...